EGFR and non-small cell lung carcinoma: <h4>Objective</h4>The application of immune checkpoint inhibitors (ICIs) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) following tyrosine kinase inhibitor (TKI) resistance remains controversial.